Oncothyreon (ONTY) Promotes VP Diana Hausman to Medical Cheif
Up)
Oncothyreon Inc. (Nasdaq: ONTY) today announced the promotion of Diana Hausman, M.D., to Chief Medical Officer. Dr. Hausman joined Oncothyreon in August 2009 as Vice President, Clinical Development.
Prior to joining Oncothyreon, Dr. Hausman was employed at Zymogenetics, Inc., Seattle, Washington, where she held a number of clinical research positions from 2005 to 2009, including Senior Director of Clinical Research. Prior to Zymogenetics, Dr. Hausman led a global drug development team at Berlex Inc. in Seattle from 2002 until 2005.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
Prior to joining Oncothyreon, Dr. Hausman was employed at Zymogenetics, Inc., Seattle, Washington, where she held a number of clinical research positions from 2005 to 2009, including Senior Director of Clinical Research. Prior to Zymogenetics, Dr. Hausman led a global drug development team at Berlex Inc. in Seattle from 2002 until 2005.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
You May Also Be Interested In
- WBB Securities Upgrades Oncothyreon (ONTY) to Hold
- Rosetta Genomics (ROSG) Names New CFO
- RIM (RIMM) Global Sales Lead Spence to Depart
Create E-mail Alert Related Categories
Management ChangesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
